Dalbavancin

Kathryn Dzintars, Pharm.D., BCPS, Paul Pham, Pharm.D.

INDICATIONS

FDA

  • Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
    • S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)

NON-FDA APPROVED USES

No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 30, 2017